Glucocorticoids-Induced Neuropsychiatric Disorders in Patients With Inflammatory Bowel Disease: A Systematic Review

Inflammatory bowel disease (IBD) is a globally rising chronic intestinal disease that affects individuals in many parts of the world. Immunosuppressive medications such as corticosteroids are used to manage flare-ups and to induce remission in IBD. Corticosteroids are said to cause several systemic...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-09, Vol.14 (9), p.e28981
Main Authors: Ali, Safina, Paul, Salomi, Yakkali, Shreyas, Teresa Selvin, Sneha, Thomas, Sonu, Bikeyeva, Viktoriya, Abdullah, Ahmed, Radivojevic, Aleksandra, Abu Jad, Anas A, Ravanavena, Anvesh, Ravindra, Chetna, Igweonu-Nwakile, Emmanuelar O, Hamid, Pousette
Format: Article
Language:English
Subjects:
Chronic illnesses
Clinical trials
Crohn's disease
Developing countries
Emotional disorders
Gastroenterology
Hyperglycemia
Immune system
Inflammation
Inflammatory bowel disease
Internal Medicine
LDCs
Lymphocytes
Mental depression
Mood disorders
Observational studies
Pathogenesis
Questionnaires
Remission (Medicine)
Steroids
Systematic review
Tumor necrosis factor-TNF
Westernization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inflammatory bowel disease (IBD) is a globally rising chronic intestinal disease that affects individuals in many parts of the world. Immunosuppressive medications such as corticosteroids are used to manage flare-ups and to induce remission in IBD. Corticosteroids are said to cause several systemic symptoms, but they are also associated with drug-induced neuropsychiatric disorders. This article examines the existing data on psychiatric and cognitive effects associated with corticosteroid therapy in relation to IBD. Many studies have found that corticosteroids appear to cause mood disturbances such as mania, hypomania, depression, and cognitive problems in the first few weeks of therapy, but these effects are dose-dependent and often mild. The purpose of this literature review is to shed light on the impact corticosteroids can have on individuals' mental health, which will aid physicians in the future when treating patients with IBD. Healthcare professionals should advise patients of this risk and assess the need for intervention. While there is evidence that corticosteroids can elicit neuropsychiatric symptoms, more data on people with IBD who are on corticosteroid therapy is needed to determine the prevalence of glucocorticoid-induced mood changes in this population.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.28981